Fujian Governor Zhao Long Visits LBE Pharma for Inspections and Guidance, Charting a New Blueprint for High-Quality Development

On June 3, 2026, Fujian Provincial Governor Zhao Long led a delegation to LBE Pharma for an inspection and research visit, offering strategic guidance and charting the company's future direction. Dr. Du Chuanjie, Chairman and President of the company, accompanied the governor and reported on the company's development strategy, scientific research innovation, and industrialization progress.

Reviewing Operations and Innovation at the Frontline: During the visit, Governor Zhao Long toured key areas of the Company and gained a comprehensive understanding of LBE Pharma's development strategy, innovative products, and manufacturing capabilities.

Strategic Briefing: At the Company's exhibition center, Dr. Du provided an overview of LBE Pharma's global development strategy, highlighting its commitment to aligning technological innovation with industry needs and translating scientific achievements into commercial value. Governor Zhao Long was introduced to the Company's core technology platforms, global business model, and international market expansion initiatives.

Product Demonstrations: Governor Zhao Long observed demonstrations of the Company's emergency auto-injector products and dual-chamber prefilled syringe formulations. The presentations showcased the scientific rationale behind product development, key technological advantages, and potential clinical applications, reflecting LBE Pharma's innovation capabilities and leadership in the field of high-value specialty formulations.

Workshop Visit: Governor Zhao toured the production workshops to inspect production line design, equipment operation, and manufacturing capacity, conducting an on-site review of the company's high-end formulation production lines.

Precision Guidance: Charting the Course for High-Quality Development

During the visit, Governor Zhao Long highly commended LBE Pharma's achievements in establishing a strong presence in Fujian Province and advancing innovation in the field of high-end pharmaceutical formulations. He recognized the company's success in overcoming international technological barriers and addressing critical gaps in China's pharmaceutical industry, particularly in emergency-use drug-device combination products and dual-chamber pre-filled syringe filling technologies. In line with the broader development goals of Fujian's biopharmaceutical sector, Governor Zhao Long also provided valuable guidance on the company's next stage of growth, helping define a clear roadmap for high-quality and sustainable development.

Corporate Commitment: Rooted in Fujian, Reaching Global Markets

Governor Zhao Long's visit is not only strong recognition from the Fujian Provincial Government of LBE Pharma's innovation achievements, but also a significant source of momentum for the company's continued growth.

Looking ahead, LBE Pharma will seize the opportunities arising from Fujian Province's efforts to foster innovation-driven growth and accelerate the development of its biopharmaceutical industry. The company remains committed to increasing investment in research and development, accelerating the global registration and commercialization of its proprietary products, expanding manufacturing capacity, and strengthening cross-strait industry-academia-research collaboration.

Leveraging the strategic location and policy advantages of the Fuzhou New Area, LBE Pharma will continue to connect pharmaceutical innovation resources from both sides of the Taiwan Strait and contribute to the development of a modern Fujian and a leading life sciences and healthcare innovation hub along China's southeastern coast.